Drug major Lupin today said it has received final approval from the US health regulator to market Clobetasol Propionate ointment, used to treat inflammation and itching caused by a number of skin conditions, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) for its product which is a generic version of Fougera Pharmaceuticals Inc's Temovate ointment, Lupin Ltd said in a statement.
The product is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
According to MAT sales data, Clobetasol Propionate ointment had annual sales of around USD 120 million in the US.
Shares of Lupin today ended 2.52 per cent down at Rs 774.65 on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app